CIP2A and ovarian carcinoma: Strong cytoplasmic CIP2A positivity indicated a reduced ovarian cancer-specific 5-year survival of 31.6% (95% CI 24.7–38.4), compared to patients with weak CIP2A positivity with a 5-year survival of 42.4% (95% CI 35.6–49.2), and to those who were negative for cytoplasmic CIP2A 5-year survival of 63.0% (95% CI 52.7–73.3; P=0.0001, log-rank test; Figure 2A).